chk1 in 6

Chk1-IN-6 is a potent, selective, and orally bioavailable [CHK1] inhibitor candidate.

CHK1-IN-2 is an inhibitor of checkpoint kinase 1 (CHK1; IC50: 6 nM).

Thalidomide-5-F-6-azetidin-MeOH is a synthetic E3 ligase ligand-linker conjugate used in the synthesis of PROTACFLT3/CHK1 Degrader-1. This compound acts as a potent FLT3/CHK1 degrader with demonstrated antitumor activity.

Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. It exhibits antiproliferative effects on MCF7, HCT116, and EKVX cancer cell lines with IC50s of 3.36 μM, 1.40 μM, and 3.49 μM, respectively. Additionally, Multi-kinase-IN-6 induces cell cycle arrest at the G1/S and G1 phases in MCF7 and HCT116 cells, respectively, and effectively triggers apoptosis [1].